<DOC>
	<DOCNO>NCT01873404</DOCNO>
	<brief_summary>The primary objective study assess efficacy Intravenous ( IV ) BG00010 ( Neublastin ) improve pain painful lumbar radiculopathy participant administer 3 time per week 1 week . The secondary objective study study population follow : To explore duration effect BG00010 improve pain ; To explore dose response curve pain reduction ; To assess safety tolerability BG00010 ; To assess serum exposure BG00010 .</brief_summary>
	<brief_title>BG00010 ( Neublastin ) Phase 2 Multiple Dose Adaptive Design Participants With Painful Lumbar Radiculopathy</brief_title>
	<detailed_description>During study , frequent assessment allocation probability conduct guide subsequent randomization participant dose group .</detailed_description>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Sciatica</mesh_term>
	<criteria>Key Body weight ≤133 kg . Leg pain radiating , diagnose due painful lumbar radiculopathy lumbosacral radiculopathy , diagnosis occur within ≥6 month ≤5 year time randomization . Objective , document evidence painful lumbar radiculopathy involvement Lower back pain Leg pain Male female subject childbearing potential must practice effective contraception study willing able continue contraception 3 month last dose study treatment . Key History positive test result screen human immunodeficiency virus , hepatitis C virus antibody , current Hepatitis B infection . Clinically significant disease condition determine investigator . Major surgery within 30 day prior Screening Visit schedule occur study . Previous participation study neurotrophic factor ( e.g. , nerve growth factor ) . Participation study another investigational drug approve therapy investigational use within 3 month prior Day 1 . Other unspecified reason , opinion Investigator Biogen Idec Inc. ( Biogen Idec ) , make subject unsuitable enrollment NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>